IRIDEX (NASDAQ:IRIX) Announces Earnings Results

IRIDEX (NASDAQ:IRIX) announced its quarterly earnings data on Thursday. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01, FiscalAI reports. The firm had revenue of $14.72 million during the quarter, compared to analyst estimates of $14.74 million. IRIDEX had a negative return on equity of 1,204.74% and a negative net margin of 10.04%.

Here are the key takeaways from IRIDEX’s conference call:

• IRIDEX delivered a transformed financial profile in 2025 with $52.7M revenue (+8% YoY), a 22% reduction in operating expenses, positive adjusted EBITDA for the year, and positive operating cash flow in Q4.
• Commercial momentum accelerated—Cyclo G6 probe sales rose to 57,800 for the year (15,900 in Q4), PASCAL retina sales and surgical-retina exceeded plan, and AAO trade-show follow-ups have converted to nearly $1M in orders.
• Gross margin pressure is a near-term headwind—Q4 gross margin fell to 37% from 44% YoY due to higher manufacturing costs, tariff impacts and inventory write-downs.
• Management is pursuing cost actions to restore margins and free cash flow, including starting a multi-year transition to third‑party contract manufacturing in 2026 (full implementation in 2027) and relocations that are expected to yield roughly $165k quarterly and ~$600k annualized in savings.
• 2026 guidance of $51M–$53M excludes Middle East sales (about 5% of revenue) and management provided inconsistent pro‑forma growth statements, creating modeling uncertainty tied to regional disruption.

IRIDEX Stock Up 1.9%

IRIX opened at $1.35 on Friday. The company has a market capitalization of $23.21 million, a PE ratio of -4.50 and a beta of 0.67. The company has a debt-to-equity ratio of 62.29, a current ratio of 1.94 and a quick ratio of 1.35. IRIDEX has a fifty-two week low of $0.79 and a fifty-two week high of $1.65. The business has a 50-day moving average of $1.41 and a 200-day moving average of $1.20.

Hedge Funds Weigh In On IRIDEX

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its stake in IRIDEX by 93.9% in the fourth quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 15,377 shares during the last quarter. Susquehanna International Group LLP boosted its position in IRIDEX by 46.2% during the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 17,834 shares during the period. Apexium Financial LP grew its holdings in IRIDEX by 53.0% during the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 34,834 shares during the last quarter. Finally, Citadel Advisors LLC grew its holdings in IRIDEX by 62.7% during the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 42,202 shares during the last quarter. Institutional investors own 20.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on IRIX shares. Weiss Ratings restated a “sell (d-)” rating on shares of IRIDEX in a report on Monday, December 29th. Alliance Global Partners began coverage on shares of IRIDEX in a research note on Thursday, February 5th. They issued a “buy” rating on the stock. Finally, iA Financial set a $3.00 target price on shares of IRIDEX in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.00.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.